Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)

被引：0
|
作者：
Ernst, S. M. [1 ]
de Bruijn, P. [2 ]
van der Horst, T. E. [1 ]
Paats, M. S. [1 ]
Aerts, J. G. [1 ]
Mathijssen, R. H. [2 ]
Koolen, S. L. [2 ]
Dingemans, A-M. C. [1 ]
机构：
[1] Erasmus MC Canc Inst, Dept Resp Med, Rotterdam, Netherlands
[2] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2430
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1398P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
    Hong, D. S.
    Bang, Y. -J.
    Barlesi, F.
    Durm, G.
    Falchook, G.
    Govindan, R.
    Dy, G.
    Park, K.
    Strickler, J.
    Burns, T.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
  • [32] Cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
    El Saadany, T.
    Lupatsch, J.
    Mark, M.
    Mehra, T.
    Schwenkglenks, M.
    von Moos, R.
    SWISS MEDICAL WEEKLY, 2023, 153 : 56S - 56S
  • [33] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Cardona, Andres Felipe
    Recondo, Gonzalo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer
    Milner-Watts, Charlotte
    O'Sullivan, Hazel
    Stewart, James
    Idaikkadar, Praveena
    Tokaca, Nadza
    Davidson, Michael
    Yousaf, Nadia
    Bhosle, Jaishree
    Popat, Sanjay
    O'Brien, Mary
    Minchom, Anna
    LUNG CANCER, 2023, 178 : S31 - S32
  • [35] Fatigue in non-small cell lung cancer (NSCLC) patients treated with immunotherapy, is there a role for physical activity?
    Calman, Lynn
    Rose, Ben
    Cave, Judith
    Evans, Owain
    LUNG CANCER, 2021, 156 : S48 - S48
  • [36] Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients
    Swart, E.
    Noordhof, A. L.
    Damhuis, R. A. M.
    Kunst, P. W. A.
    De Ruysscher, D. K. M.
    Hendriks, L. E. L.
    van Geffen, W. H.
    Aarts, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S349 - S349
  • [37] A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
    Markman, B.
    Solomon, B.
    Nott, L. M.
    Roberts-Thomson, R.
    Hughes, B.
    Pavlakis, N.
    Davis, A.
    Brown, L. J.
    Parakh, S.
    Brungs, D.
    Bowyer, S. E.
    Nordman, I.
    Jennens, R.
    Warburton, L.
    Harris, S. J.
    Samuel, E.
    Ramanujam, S.
    Wang, A.
    Dumas, M.
    Gard, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1700 - S1700
  • [38] Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy
    Glick, D.
    Wall, E.
    Lesperance, M.
    Croteau, N.
    Brooks, E.
    Fenton, D.
    Fiorino, L.
    Geller, G.
    Poonja, Z.
    Ksienski, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S469 - S469
  • [39] Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)
    Dehem, Agathe
    Mazieres, Julien
    Chour, Ali
    Guisier, Florian
    Ferreira, Marion
    Boussageon, Maxime
    Girard, Nicolas
    Moro-Sibilot, Denis
    Cadranel, Jacques
    Zalcmanl, Gerard
    Ricordel, Charles
    Wislez, Marie
    Munck, Camille
    Poulet, Claire
    Gauvain, Clement
    Descarpentries, Clotilde
    Wasielewski, Eric
    Cortot, Alexis B.
    Baldacci, Simon
    LUNG CANCER, 2023, 186
  • [40] NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes
    Dehem, A.
    Mazieres, J.
    Chour, A.
    Guisier, F.
    Ferreira, M.
    Boussageon, M.
    Girard, N.
    Moro-Sibilot, D.
    Cadranel, J.
    Zalcman, G.
    Ricordel, C.
    Wislez, M.
    Munck, C.
    Poulet, C-H.
    Gauvain, C.
    Descarpentries, C.
    Wasielewski, E.
    Cortot, A. B.
    Baldacci, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1023 - S1024
12345